A Strong Product Pipeline, Solid Upside And Attractive Valuation Could Make This Biotech A Buy

With nine FDA-approved products and more than 30 product candidates in clinical development – including a potential COVID-19 therapeutic – the biotechnology company featured in today’s article has seen impressive historical growth. And with several recent positive developments, and solid upside to its consensus price target, this stock, which is currently trading at a discount to its peers, may be a buy now. For more, CLICK HERE.